PDL SP142

PDL SP142 Alternative Name PD-L1 SP142 FDA (TECENTRIQ®) Methodology Immunohistochemistry (IHC) Test Description Disease non-small cell lung cancer (NSCLC)PD-L1 (SP142) Assay is a qualitative immunohistochemical

FLT3 Mutation Analysis-FLT3-ITD

FLT3 Mutation Analysis-FLT3-ITD Methodology Molecular Test Description Genes FLT3 (ITD variants , exon14,15) Disease acute myeloid leukemiaA polymerase chain reaction test aiming for detection of mutations

FLT3 Mutation Analysis-FLT3-TKD (D835 and I836 mutations)

FLT3 Mutation Analysis-FLT3-TKD (D835 and I836 mutations) Methodology Molecular Test Description Genes FLT3 TKD variants (D835 and I836 mutations) Disease acute myeloid leukemiaA polymerase chain reaction

JAK2 V617F Mutation Analysis reflex to CALR and MPL mutation analysis

JAK2 V617F Mutation Analysis reflex to CALR and MPL mutation analysis Methodology Molecular Test Description Genes JAK2 V617F & CALR & MPL Disease myeloproliferative neoplasm, polycythemia vera, acute

JAK2 V617F Mutation analysis reflex to CALR, MPL & all MPN genes

JAK2 V617F Mutation analysis reflex to CALR, MPL & all MPN genes Methodology Molecular Test Description Genes ABL1, ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CBL, CBLB, CBLC, CDKN2A, CSF3R, CUX1, CXCR4, DDX41,

JAK2 V617F Mutation Analysis reflex to exons 12, 13 & 15

JAK2 V617F Mutation Analysis reflex to exons 12, 13 & 15 Methodology Molecular Test Description Genes JAK2 V617F & JAK-2 exon 12, 13,15 Disease myeloproliferative neoplasm, polycythemia vera, acute myeloid

BCR/ABL p190 (minor)

BCR/ABL p190 (minor) Methodology Molecular Test Description Genes BCR/ABL1 (t(9;22)) Minor (p190) breakpoints Disease B-cell lymphoblastic leukemia/lymphoma, and acute myeloid leukemia ,MPNA polymerase

BCR/ABL p210 (major)

BCR/ABL p210 (major) Methodology Molecular Test Description Genes BCR/ABL1 (t(9;22) Major (p210) breakpoints Disease B-cell lymphoblastic leukemia/lymphoma, and acute myeloid leukemia ,MPNA polymerase

BCR/ABL p210 (major) reflex to ABL Kinase Muation Panel

BCR/ABL p210 (major) reflex to ABL Kinase Muation Panel Methodology Molecular Test Description Genes BCR/ABL1 (t(9;22) Major (p210) breakpoints & ABL Kinase gene Disease B-cell lymphoblastic leukemia/lymphoma,

Methodology Molecular Test Description Genes ABL1, ANKRD26, ASXL1, BCOR, BCORL1, BRAF, CBL, CBLB, CBLC, CDKN2A, CSF3R, CUX1, CXCR4, DDX41, DNMT3A, ETNK1, ETV6, EZH2, FBXW7, FLT3, GATA1, GATA2, GNAS, GNB1,

BCR/ABL p210 (major) reflex to BCR/ABL p190 (minor)

BCR/ABL p210 (major) reflex to BCR/ABL p190 (minor) Methodology Molecular Test Description Genes BCR/ABL1 (t(9;22) Major (p210) breakpoints & Minor (p190) breakpoints Disease B-cell lymphoblastic leukemia/lymphoma,

IGH (B-Cell Gene rearrangement)

IGH (B-Cell Gene rearrangement) Methodology Molecular Test Description Genes IGH Disease diffuse large B-cell lymphoma, follicular lymphoma, mature B-cell neoplasm, breast invasive ductal carcinoma, and

TCRB Gene rearrangement

TCRB Gene rearrangement Methodology Molecular Test Description Genes TCRB Disease T-cell neoplasmT-cell Receptor (TCR) Beta Gene Rearrangement, PCR is useful for establishing clonality of T-cell lymphoid

TCRG Gene rearrangement

TCRG Gene rearrangement Methodology Molecular Test Description Genes TCRG Disease T-cell neoplasmT-cell Clonality Panel (TCRB, TCRG), interrogates both the T-cell receptor beta (TCRB) locus and the T-cell

TCRG Gene rearrangement reflex to TCRB Gene rearrangement

TCRG Gene rearrangement reflex to TCRB Gene rearrangement Methodology Molecular Test Description Genes TCRG reflex to TCRB Disease T-cell neoplasmT-cell Clonality Panel (TCRB, TCRG), interrogates both

CALR Mutation Analysis

CALR Mutation Analysis Methodology Molecular Test Description Genes CALR Disease Essential Thrombocythemia , Primary MyelofibrosisThe calreticulin gene, called CALR , is responsible for making a protein

JAK-2 V617F Mutation Analysis

JAK-2 V617F Mutation Analysis Methodology Molecular Test Description Genes JAK-2 V617F Disease myeloproliferative neoplasm, polycythemia vera, acute myeloid leukemia, overt primary myelofibrosis, and essential

MPL Mutation Analysis

MPL Mutation Analysis Methodology Molecular Test Description Genes MPL common variants (eg, W515A, W515K, W515L, W515R) Disease MPNThe thrombopoietin receptor also known as the myeloproliferative leukemia

JAK2 Exon 12 Mutation Analysis

JAK2 Exon 12 Mutation Analysis Methodology Molecular Test Description Genes JAK2 Exon 12 Disease PVMutations within exon 12 of the JAK2 gene occur in most cases of JAK2 V617F-mutation negative polycythemia

JAK2 Exon 13, 15 (NGS) Mutation Analysis

JAK2 Exon 13, 15 (NGS) Mutation Analysis Methodology Molecular Test Description Genes JAK2 Exon 13, 15 Disease PVA small percentage (~3.3%) of JAK2 mutation positive patient contain other non-V617F mutations

BRAF HCL

BRAF HCL Methodology Molecular Test Description Genes BRAF HCL (V600E) Disease Hairy Cell LukemiaBRAF V600E is the defining driver mutation in classic Hairy Cell Leukemia (HCL), present in the vast majority

CSF3R

CSF3R Methodology Molecular Test Description Genes CSF3R Disease chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML).Colony Stimulating Factor 3 Receptor (CSF3R) encodes the

IDH1/IDH2

IDH1/IDH2 Methodology Molecular Test Description Genes IDH1/IDH2 Disease AMLIsocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are metabolic enzymes frequently mutated in cancers such as acute myeloid leukemia,

IGHV hypermutation

IGHV hypermutation Methodology Molecular Test Description Genes IGHV hypermutation Disease CLLImmunoglobulin Heavy Chain Variable Region (IGHV) hypermutation status is an important biomarker in chronic

KIT D816X

KIT D816X Methodology Molecular Test Description Genes KIT D816X Disease systemic mastocytosis and other myeloid neoplasms.KIT encodes a receptor tyrosine kinase that regulates cell growth and survival.